n euromuscular e mergencies july 28, 2010 sandra derghazarian
TRANSCRIPT
![Page 1: N EUROMUSCULAR E MERGENCIES July 28, 2010 Sandra Derghazarian](https://reader031.vdocuments.net/reader031/viewer/2022013011/56649ccb5503460f94994bbf/html5/thumbnails/1.jpg)
NEUROMUSCULAR EMERGENCIES
July 28, 2010Sandra Derghazarian
![Page 2: N EUROMUSCULAR E MERGENCIES July 28, 2010 Sandra Derghazarian](https://reader031.vdocuments.net/reader031/viewer/2022013011/56649ccb5503460f94994bbf/html5/thumbnails/2.jpg)
Outline
• Approach to rapidly progressing LMN weakness
• Myasthenic crisis• GBS
![Page 3: N EUROMUSCULAR E MERGENCIES July 28, 2010 Sandra Derghazarian](https://reader031.vdocuments.net/reader031/viewer/2022013011/56649ccb5503460f94994bbf/html5/thumbnails/3.jpg)
Intro
• Three major tasks:– Assess stability, signs of imminent resp failure– Generate differential diagnosis• Knowledge of localisation• Knowledge of major disorders
– Determine management
![Page 4: N EUROMUSCULAR E MERGENCIES July 28, 2010 Sandra Derghazarian](https://reader031.vdocuments.net/reader031/viewer/2022013011/56649ccb5503460f94994bbf/html5/thumbnails/4.jpg)
Brief Review of Anatomy
• Motor unit anatomy– Anterior horn cell– Its motor axon – The synaptic cleft– The muscle fibers it innervates
• Remember sensory and autonomic systems– Many disorder with rapidly progressing peripheral
neuropathic weakness will have sensory loss and dysautonomia
![Page 5: N EUROMUSCULAR E MERGENCIES July 28, 2010 Sandra Derghazarian](https://reader031.vdocuments.net/reader031/viewer/2022013011/56649ccb5503460f94994bbf/html5/thumbnails/5.jpg)
Classification• Motor neuron– Loss of anterior horn cells
• Motor axon– Disruption of myelin sheath– Axonal degeneration
• Neuromuscular junction– Pre-synaptic (e.g. Release of Ach)– Post-synaptic (e.g. Abnormalities of Ach receptor)
• Muscle– Membrane, contractile elements– Genetic or acquired secondary (infex, inflamm, vasc.)
![Page 6: N EUROMUSCULAR E MERGENCIES July 28, 2010 Sandra Derghazarian](https://reader031.vdocuments.net/reader031/viewer/2022013011/56649ccb5503460f94994bbf/html5/thumbnails/6.jpg)
Approach to Determining Cause of Weakness
• Knowledge of some of the possible disorders• Focused history• Physical exam• Lab studies
![Page 7: N EUROMUSCULAR E MERGENCIES July 28, 2010 Sandra Derghazarian](https://reader031.vdocuments.net/reader031/viewer/2022013011/56649ccb5503460f94994bbf/html5/thumbnails/7.jpg)
Major DisordersLevel of motor unit Disorders causing rapidly progressing weakness
Motor neuron ALSPoliomyelitis, West Nile virus
Peripheral nerve Guillain-Barre syndrome/AIDPTick paralysisDiphtheric, porphyric, arsenic neuropathyShellfish poisoning
Neuromuscular junction
Myasthenia gravisBotulismLambert-Eaten myasthenic syndromeHypermagnesemia
Muscle Acquired: Dermato- and polymyositis, Myoglobinuric myopathy, Hypokalemic paralysis, Toxic myopathy, Acute myopathy of intensive careGenetic disorders: X-linked dystrophies, myotonic dystrophy, acid maltase deficiency, mitochondrial
![Page 8: N EUROMUSCULAR E MERGENCIES July 28, 2010 Sandra Derghazarian](https://reader031.vdocuments.net/reader031/viewer/2022013011/56649ccb5503460f94994bbf/html5/thumbnails/8.jpg)
History – Key Elements• Pre-existing NM disorder?
– MG – exacerbation 2ary systemic illness, medication– ALS – accelerated phase, decompensation 2ary pneumonia
• Pre-existing systemic disorder?– Malignancy, CTD, sepsis
• What drugs is pt taking?• Any recent illness?• Diet in last 48 hours?
– Shellfish (saxitoxin, brevetoxin)– Home-canned goods (botulinum toxin)
• Any possible exposure to tick bite, snake bite?• Any sensory or autonomic symptoms?
![Page 9: N EUROMUSCULAR E MERGENCIES July 28, 2010 Sandra Derghazarian](https://reader031.vdocuments.net/reader031/viewer/2022013011/56649ccb5503460f94994bbf/html5/thumbnails/9.jpg)
Drugs• Diuretics – Hypokalemia
• Corticosteroids, statins, colchicine, cyclosporine, cocaine, chloroquine, L-tryptophan, penicillamine, zidovudine– Myotoxic effect
• Amiodarone, cytarabine, streptokinase – Demyelinating neuropathy
• Magnesium-containing antacids with pre-existing renal insufficiency – Hypermagnesemia
![Page 10: N EUROMUSCULAR E MERGENCIES July 28, 2010 Sandra Derghazarian](https://reader031.vdocuments.net/reader031/viewer/2022013011/56649ccb5503460f94994bbf/html5/thumbnails/10.jpg)
Physical Exam
• Vital signs– Unstable?– Dysautonomia?
• Respiratory status
![Page 11: N EUROMUSCULAR E MERGENCIES July 28, 2010 Sandra Derghazarian](https://reader031.vdocuments.net/reader031/viewer/2022013011/56649ccb5503460f94994bbf/html5/thumbnails/11.jpg)
Signs of impending NM resp failure• Tachypnea, sinus tachycardia• Staccato speech• Inability to count to 20• Profound weakness of neck flexion• Use of accessory muscles (visible, palpable)• Orthopnea• Paradoxical breathing pattern• Signs of bulbar dysfunction (nasal voice,
accumulation of saliva, weak cough) – think about aspiration!
![Page 12: N EUROMUSCULAR E MERGENCIES July 28, 2010 Sandra Derghazarian](https://reader031.vdocuments.net/reader031/viewer/2022013011/56649ccb5503460f94994bbf/html5/thumbnails/12.jpg)
Physical Exam
![Page 13: N EUROMUSCULAR E MERGENCIES July 28, 2010 Sandra Derghazarian](https://reader031.vdocuments.net/reader031/viewer/2022013011/56649ccb5503460f94994bbf/html5/thumbnails/13.jpg)
Physical Exam
• Vital signs • Note any dysautonomia
• Presence and pattern muscle weakness• Proximal (myopathy), distal (peripheral neuropathy)• Symmetric, asymmetric• Involvement of cranial muscles
• Reflexes• Sensory changes• Dysautonomia
![Page 14: N EUROMUSCULAR E MERGENCIES July 28, 2010 Sandra Derghazarian](https://reader031.vdocuments.net/reader031/viewer/2022013011/56649ccb5503460f94994bbf/html5/thumbnails/14.jpg)
Localisation of the Disorders• Clinical picture varies depending on which part of
motor unit is involved
Level of motor unit Key Clinical Feature
Motor neuron Predominantly motor signsOften asymmetricOccasional sensory signsDTRs may be increased if ALS
Peripheral nerve Weakness and sensory signs+/- autonomic signs+/- cranial musclesDTRs reduced or lost
![Page 15: N EUROMUSCULAR E MERGENCIES July 28, 2010 Sandra Derghazarian](https://reader031.vdocuments.net/reader031/viewer/2022013011/56649ccb5503460f94994bbf/html5/thumbnails/15.jpg)
Localisation ctn’dLevel of motor unit Key Clinical Features
Neuromuscular junction Involve cranial, limb girdle, proximal muscles+/- respiratory musclesNormal sensation(If presynaptic: +ve autonomic signs and post-exercise increase in strengthIf post-synaptic: fatigability)
Muscle Predilection for neck, limb girdle, proximal musclesNormal sensationPossible cardiomyopathyOccasional resp muscle involvementPossible risk of myoglobinuria
![Page 16: N EUROMUSCULAR E MERGENCIES July 28, 2010 Sandra Derghazarian](https://reader031.vdocuments.net/reader031/viewer/2022013011/56649ccb5503460f94994bbf/html5/thumbnails/16.jpg)
![Page 17: N EUROMUSCULAR E MERGENCIES July 28, 2010 Sandra Derghazarian](https://reader031.vdocuments.net/reader031/viewer/2022013011/56649ccb5503460f94994bbf/html5/thumbnails/17.jpg)
Regroup
• Is respiratory failure imminent?• Should ICU be involved?• Where can I localise motor findings?• Does it fit with sensory findings?• Does it fit with autonomic findings?• Does it fit with the history? • Can the history help me narrow things down?
![Page 18: N EUROMUSCULAR E MERGENCIES July 28, 2010 Sandra Derghazarian](https://reader031.vdocuments.net/reader031/viewer/2022013011/56649ccb5503460f94994bbf/html5/thumbnails/18.jpg)
Major DisordersLevel of motor unit Disorders causing rapidly progressing weakness
Motor neuron ALSPoliomyelitis
Peripheral nerve Guillain-Barre syndromeTick paralysisDiphtheric, porphyric, arsenic neuropathyShellfish poisoning
Neuromuscular junction
Myasthenia gravisBotulismLambert-Eaten myasthenic syndromeHypermagnesemia
Muscle Acquired: Dermato- and polymyositis, Myoglobinuric myopathy, Hypokalemic paralysis, Toxic myopathy, Acute myopathy of intensive careGenetic disorders: X-linked dystrophies, myotonic dystrophy, acid maltase deficiency, mitochondrial
![Page 19: N EUROMUSCULAR E MERGENCIES July 28, 2010 Sandra Derghazarian](https://reader031.vdocuments.net/reader031/viewer/2022013011/56649ccb5503460f94994bbf/html5/thumbnails/19.jpg)
Laboratory Studies• CBC
• Anemia or leukocytosis - systemic disease• Eosinophilia - possibly elevated in vasculitic neuropathy, porphyria
• Lytes, Cr, BUN, Ca, Mg, PO4,• Liver enzymes (consider EtOH myotoxicity)• CK (myopathy if very elevated)• ESR (infectious or inflammatory disorders)• CXR (pneumonia, atelectasis, elevated hemidiaphragm)• EKG
– Changes associated with electrolyte imbalances– Arrythmias 2ary to dysautonomia in GBS– Axis deviation – may be suggestive of cardiomyopathy
![Page 20: N EUROMUSCULAR E MERGENCIES July 28, 2010 Sandra Derghazarian](https://reader031.vdocuments.net/reader031/viewer/2022013011/56649ccb5503460f94994bbf/html5/thumbnails/20.jpg)
Assess Respiratory Status
• Tests in ER– MIP– MEP– FVC– ABG
• 20/30/40 rule– VC: 20 ml/kg– MIP: -30cmH20– MEP: +40cm H20
![Page 21: N EUROMUSCULAR E MERGENCIES July 28, 2010 Sandra Derghazarian](https://reader031.vdocuments.net/reader031/viewer/2022013011/56649ccb5503460f94994bbf/html5/thumbnails/21.jpg)
MYASTHENIC CRISIS
![Page 22: N EUROMUSCULAR E MERGENCIES July 28, 2010 Sandra Derghazarian](https://reader031.vdocuments.net/reader031/viewer/2022013011/56649ccb5503460f94994bbf/html5/thumbnails/22.jpg)
Myasthenia Gravis
• Disorder of transmission across NM junction• Auto-immune and congenital form• Epidemiology (auto-immune form): – 200-400 cases per million population– Women > men (3:2)– Bimodal incidence• F: 20s, 30s; M: 50s, 60s
– 5-10% co-association with other auto-immune disorders
![Page 23: N EUROMUSCULAR E MERGENCIES July 28, 2010 Sandra Derghazarian](https://reader031.vdocuments.net/reader031/viewer/2022013011/56649ccb5503460f94994bbf/html5/thumbnails/23.jpg)
Classification
• Auto-immune – two forms– Acquired anti-AChR Abs (85%)– Acquired anti-MuSK Abs, a muscle-specific TK• 40-50% of anti-AChR seronegative pts
• Congenital– Heterogeneous group (pre or post-synaptic)– Of note: do not affect respiratory muscles
therefore do not present with myasthenic crisis
![Page 24: N EUROMUSCULAR E MERGENCIES July 28, 2010 Sandra Derghazarian](https://reader031.vdocuments.net/reader031/viewer/2022013011/56649ccb5503460f94994bbf/html5/thumbnails/24.jpg)
Clinical Features
• Painless, fatigable weakness of voluntary muscles– Repeated activity progressive paresis– Rest restoration of strength (at least partial)
• Usually insidious onset– May occur more rapidly after precipitant (stress,
infection)
• Association with thymic abnormalities– 10-15% thymoma– 50-70% thymic lymphoid hyperplasia
![Page 25: N EUROMUSCULAR E MERGENCIES July 28, 2010 Sandra Derghazarian](https://reader031.vdocuments.net/reader031/viewer/2022013011/56649ccb5503460f94994bbf/html5/thumbnails/25.jpg)
Clinical Features• Presenting symptoms:
• MuSK-MG– Younger women– Predominantly facial, bulbar and respiratory weakness– Relatively mild limb weakness
Diplopia 50-64%Ptosis 50-64%Generalised weakness 35%Leg weakness 10%Fatigue 9%Respiratory failure 1%
![Page 26: N EUROMUSCULAR E MERGENCIES July 28, 2010 Sandra Derghazarian](https://reader031.vdocuments.net/reader031/viewer/2022013011/56649ccb5503460f94994bbf/html5/thumbnails/26.jpg)
Severity Classification
![Page 27: N EUROMUSCULAR E MERGENCIES July 28, 2010 Sandra Derghazarian](https://reader031.vdocuments.net/reader031/viewer/2022013011/56649ccb5503460f94994bbf/html5/thumbnails/27.jpg)
Myasthenic Crisis
• Myasthenic weakness leading to respiratory failure and need for ventilatory assistance
• Severe weakness of respiratory musclesand/or
• Severe weakness of upper airway muscles (bulbar myasthenia)
![Page 28: N EUROMUSCULAR E MERGENCIES July 28, 2010 Sandra Derghazarian](https://reader031.vdocuments.net/reader031/viewer/2022013011/56649ccb5503460f94994bbf/html5/thumbnails/28.jpg)
Prevalence and Characteristics
• Life-time prevalence: 20-30%– Early onset younger pt, median onset w/in 8
mos, fast recovery– Late onset older pts, later in dz course, slower
recovery
• White pts respond more poorly than black pts• Pregnancy aggravates MG in 30% of women– High potential mortality of crisis
![Page 29: N EUROMUSCULAR E MERGENCIES July 28, 2010 Sandra Derghazarian](https://reader031.vdocuments.net/reader031/viewer/2022013011/56649ccb5503460f94994bbf/html5/thumbnails/29.jpg)
Precipitants • Elements to look for in history/chart:– Poor control of generalised disease– Medical treatment for bulbar myasthenia
• Steroids and anti-cholinesterases– Use of certain drugs (next slide)– Systemic infection, esp. of respiratory tract– Aspiration– Surgery– Others (in refractory myasthenia):
• Emotional stress• Hot environment• Hyperthyroidism
![Page 30: N EUROMUSCULAR E MERGENCIES July 28, 2010 Sandra Derghazarian](https://reader031.vdocuments.net/reader031/viewer/2022013011/56649ccb5503460f94994bbf/html5/thumbnails/30.jpg)
Drugs
• Anticholinesterases can also lead to myasthenic crisis• Signs of excessive cholinergic activity
– Miosis, diarrhea, salivation, abdominal cramps, sweating, weakness
![Page 31: N EUROMUSCULAR E MERGENCIES July 28, 2010 Sandra Derghazarian](https://reader031.vdocuments.net/reader031/viewer/2022013011/56649ccb5503460f94994bbf/html5/thumbnails/31.jpg)
Investigations
• CBC, extended lytes, BUN, Cr, liver enzymes• CXR, U/A +/- blood cultures • Obtain VC, MIP, MEP – 20/30/40 rule
![Page 32: N EUROMUSCULAR E MERGENCIES July 28, 2010 Sandra Derghazarian](https://reader031.vdocuments.net/reader031/viewer/2022013011/56649ccb5503460f94994bbf/html5/thumbnails/32.jpg)
Investigations• Repetitive motor nerve stimulation
– Stimulate motor nerve at 2-3 Hz and measure CMAP of stimulated muscle
– Positive if >er 10% decrement in amplitude of CMAP from the 1st to the 5th potential
– Positive in about 75% of patients with generalized MG, if – Proximal & clinically involved muscles are tested – Muscle is warm – More than one muscle is tested
• Single fibre EMG• Tensilon test not recommended in pt suspected of being in crisis
– False postive, false negative– Risk of worsening muscle weakness in pts with anticholinesterase
overdose– Worsening of bulbar and respiratory symptoms in MuSK-MG
![Page 33: N EUROMUSCULAR E MERGENCIES July 28, 2010 Sandra Derghazarian](https://reader031.vdocuments.net/reader031/viewer/2022013011/56649ccb5503460f94994bbf/html5/thumbnails/33.jpg)
Management
• Monitoring of respiratory status– Recognition of impending resp failure• Tachypnea, inability to count to 20, saliva pooling, nasal
voice, NF weakness, paradoxical breathing– Deciding when to intubate• (Code status)• 20/30/40 rule• If in doubt, intubate• ?BiPAP
– Limited experience. May reduce prolonged intubatn and trach
![Page 34: N EUROMUSCULAR E MERGENCIES July 28, 2010 Sandra Derghazarian](https://reader031.vdocuments.net/reader031/viewer/2022013011/56649ccb5503460f94994bbf/html5/thumbnails/34.jpg)
Management
• General– Stop any meds that may be contributing– Treat any infection
• Specific– PLEX and IVIG comparable efficacy• Based on clinical evidence, few RTCs• Earlier response seen with PLEX
– More likely to extubate at 14 days, better 1-month functional outcome (Qureshi, et al. Neurology, 1999).
![Page 35: N EUROMUSCULAR E MERGENCIES July 28, 2010 Sandra Derghazarian](https://reader031.vdocuments.net/reader031/viewer/2022013011/56649ccb5503460f94994bbf/html5/thumbnails/35.jpg)
Management
• PLEX– Removal of anti AChR and antiMuSK Abs– 1 session/day x 5• No superiority of PLEX qd x 5 vs qod x 5
– Rapid onset of action (3-10 days)– Need central line with associated complications• PTX, hemorrhage, line sepsis
– Caution in pts with sepsis, hypotension; may lead to increased bleeding and cardiac arrhythmias
![Page 36: N EUROMUSCULAR E MERGENCIES July 28, 2010 Sandra Derghazarian](https://reader031.vdocuments.net/reader031/viewer/2022013011/56649ccb5503460f94994bbf/html5/thumbnails/36.jpg)
Management
• IVIG– 0.4gm/kg/day x 5 days– Easily administered and widely available– Long duration of action • May last as long as 30 days
– Side effects• Anaphylaxis in IgA deficiency• Renal failure, pulmonary edema• Aseptic meningitis• Thrombotic complications and stroke
![Page 37: N EUROMUSCULAR E MERGENCIES July 28, 2010 Sandra Derghazarian](https://reader031.vdocuments.net/reader031/viewer/2022013011/56649ccb5503460f94994bbf/html5/thumbnails/37.jpg)
MG – Overall Treatment Summary• 1. Mild weakness: cholinesterase inhibitors• 2. Moderate-marked localized or generalized weakness
– Cholinesterase inhibitors, and– Thymectomy for patients under age 50-60 yrs
• 3. Symptoms uncontrolled on cholinesterase inhibitors– Prednisone if severe or urgent– Azathioprine
• Prednisone failure• Excessive prednisone side-effects
• 4. Plasma exchange or IV Ig– Impending crisis; crisis– Pre-operative boost– Chronic disease refractory to drug therapy
• 5. If above fails– Search for residual thymus tissue– Cyclosporine or mycophenylate mofetil(Sem. Neurol., 2001;21:425-440)
![Page 38: N EUROMUSCULAR E MERGENCIES July 28, 2010 Sandra Derghazarian](https://reader031.vdocuments.net/reader031/viewer/2022013011/56649ccb5503460f94994bbf/html5/thumbnails/38.jpg)
Guillain-Barre Syndrome
![Page 39: N EUROMUSCULAR E MERGENCIES July 28, 2010 Sandra Derghazarian](https://reader031.vdocuments.net/reader031/viewer/2022013011/56649ccb5503460f94994bbf/html5/thumbnails/39.jpg)
GBS• Most common cause of acute and subacute
generalised paralysis• Incidence of 0.4 to 1.7/100 000 per yr• Worldwide, all ages, both sexes• Preceding mild resp or GI infection in 60% (1-3 wks)– Campylobacter jejuni (26%), – CMV, EBV, VZV – Influenza, cocksackie, hepatitis A and B, HIV
• May also be preceded by:– Surgery– Immunisations
![Page 40: N EUROMUSCULAR E MERGENCIES July 28, 2010 Sandra Derghazarian](https://reader031.vdocuments.net/reader031/viewer/2022013011/56649ccb5503460f94994bbf/html5/thumbnails/40.jpg)
Typical Symptoms & Signs
• Sensory– Paresthesias and slight numbness distally earliest Sx– Reduced proprioception and vibration sense (1 wk)
• Motor– Weakness
• Evolves symmetrically over days to 1-2 weeks• Usually LE before UE, proximal + distal• +/- trunk, intercostal, neck, cranial muscles
– Progresses to total motor paralysis and respiratory failure in 5% of cases
![Page 41: N EUROMUSCULAR E MERGENCIES July 28, 2010 Sandra Derghazarian](https://reader031.vdocuments.net/reader031/viewer/2022013011/56649ccb5503460f94994bbf/html5/thumbnails/41.jpg)
Typical Symptoms & Signs
• Reflexes– Reduced and then absent
• Autonomic dysregulation– Sinus tachycardia/bradycardia, facial flushing,
labile BP, excess or loss of sweating, urinary retention
– Usually do not persist for >er 1 wk• Other– Myalgias (50%) in hips, thighs, back
![Page 42: N EUROMUSCULAR E MERGENCIES July 28, 2010 Sandra Derghazarian](https://reader031.vdocuments.net/reader031/viewer/2022013011/56649ccb5503460f94994bbf/html5/thumbnails/42.jpg)
Variants• Fisher syndrome
– Ophthalmoplegia, ataxia, areflexia– +/- bilateral facial nerve paresis– Associated with anti-GQ1b Ab
• Acute motor sensory axonal neuropathy (5% of GBS cases)– Severe and diffuse axonal damage– Abrupt and explosive onset– Severe paralysis, minor sensory features– Slow and poor recovery
• Pandysautonomia– Severe orthostatic hypotension, anhidrosis, dry eyes and mouth, fixed pupils,
arrhythmia, bowel/bladder dysfunction– Areflexia without somatic motor/sensory involvement
• Other variants:– Initial cervico-brachial-pharyngeal muscle involvement– Generalised ataxia without dysarthria or nystagmus– Facial and abducens weakness, distal paresthesias, proximal leg weakness
![Page 43: N EUROMUSCULAR E MERGENCIES July 28, 2010 Sandra Derghazarian](https://reader031.vdocuments.net/reader031/viewer/2022013011/56649ccb5503460f94994bbf/html5/thumbnails/43.jpg)
Laboratory Findings• Most important: CSF, EMG• CSF– Normal pressure– Protein
• Early (1st 2 days): Usually normal (>85%)• Later: High (66% in 1st week, 82% in 2nd week)• Amount not correlated with clinical course or prognosis
– Acellular or few lymphocytes• 10% : 10-50 lymphocytes, decreases over 2-3 days; if not:
other Dx– Oligoclonal bands (10-30%)
![Page 44: N EUROMUSCULAR E MERGENCIES July 28, 2010 Sandra Derghazarian](https://reader031.vdocuments.net/reader031/viewer/2022013011/56649ccb5503460f94994bbf/html5/thumbnails/44.jpg)
Laboratory Findings
• EMG– Abnormalities seen within first week of sx– Reduction in motor amplitude– Slowed conduction velocities– Conduction block in motor nerves– Prolonged distal latencies (distal conduction
block)– Prolonged/absent F-responses (involvement of
proximal parts of nerves and roots)
![Page 45: N EUROMUSCULAR E MERGENCIES July 28, 2010 Sandra Derghazarian](https://reader031.vdocuments.net/reader031/viewer/2022013011/56649ccb5503460f94994bbf/html5/thumbnails/45.jpg)
Laboratory Findings
• Hematology– Abnormal only with infection or other disorder
• Biochemistry – Mild-severe SIADH in 7-26%
• Liver enzymes – Elevated <10% reflecting CMV or EBV infection
• ESR: Normal unless co-existing process
![Page 46: N EUROMUSCULAR E MERGENCIES July 28, 2010 Sandra Derghazarian](https://reader031.vdocuments.net/reader031/viewer/2022013011/56649ccb5503460f94994bbf/html5/thumbnails/46.jpg)
Diagnostic Criteria• National Institute of Neurological Disorders and Stroke (NINDS) criteria are based
on expert consensus.• Required features include:
– Progressive weakness of more than one limb, ranging from minimal weakness of the legs to total paralysis of all four limbs, the trunk, bulbar and facial muscles, and external ophthalmoplegia
– Areflexia. While universal areflexia is typical, distal areflexia with hyporeflexia at the knees and biceps will suffice if other features are consistent.
• Supportive features include:– Progression of symptoms over days to four weeks – Relative symmetry – Mild sensory symptoms or signs – Cranial nerve involvement, especially bilateral facial nerve weakness – Recovery starting two to four weeks after progression halts – Autonomic dysfunction – No fever at the onset – Elevated protein in CSF with a cell count <10 mm3 – Electrodiagnostic abnormalities consistent with GBS
![Page 47: N EUROMUSCULAR E MERGENCIES July 28, 2010 Sandra Derghazarian](https://reader031.vdocuments.net/reader031/viewer/2022013011/56649ccb5503460f94994bbf/html5/thumbnails/47.jpg)
Differential Diagnosis
• Features suggesting another diagnosis:– Sensory level, severe bladder or bowel dysfunction
Spinal cord syndrome– Marked asymmetry Mononeuritis
multiplex/vasculitis– CSF pleocytosis Infectious disorders: viral, HIV,
lyme, poliomyelitis– Very slow nerve conduction velocities, multiple
relapses or chronic course -> CIDP– Persistent abdominal pain and psychiatric signs
Acute intermittent porphyria
![Page 48: N EUROMUSCULAR E MERGENCIES July 28, 2010 Sandra Derghazarian](https://reader031.vdocuments.net/reader031/viewer/2022013011/56649ccb5503460f94994bbf/html5/thumbnails/48.jpg)
Management
• General:– Recommend admission for observation
• Can deteriorate rapidly in first days of presentation• M&M: Respiratory failure, dysautonomia• 25% will require mechanical ventilation
• Respiratory– Measure MIP/MEP/FVC
• Decision to intubate should be based on downward trend– Other measures of respiratory status same
• Counting to 20, strength of NF
![Page 49: N EUROMUSCULAR E MERGENCIES July 28, 2010 Sandra Derghazarian](https://reader031.vdocuments.net/reader031/viewer/2022013011/56649ccb5503460f94994bbf/html5/thumbnails/49.jpg)
Management
• Dysautonomia– 10% develop hypotension• Volume, +/- pressors
– Hypertension• IV labetolol
• Other complications– Adynamic ileus– PE– Aspiration
![Page 50: N EUROMUSCULAR E MERGENCIES July 28, 2010 Sandra Derghazarian](https://reader031.vdocuments.net/reader031/viewer/2022013011/56649ccb5503460f94994bbf/html5/thumbnails/50.jpg)
Management
• PLEX and IVIG– No difference in efficacy between the two– Indications for prompt initiation• Respiratory failure• Bulbar involvement• Inability to walk without assistance• Usually see these signs day 5-10• May occur anywhere from day 1 – week 3
• Steroids– No proven benefit
![Page 51: N EUROMUSCULAR E MERGENCIES July 28, 2010 Sandra Derghazarian](https://reader031.vdocuments.net/reader031/viewer/2022013011/56649ccb5503460f94994bbf/html5/thumbnails/51.jpg)
PLEX• Regimen: 4-6 treatments on alternate days• Established usefulness in evolving phase• If treated within 2 wks onset– Decrease in LOS, ventilation, time to independent
ambulation by approx. half• Value less clear if started later than 2 wks after
initial symptoms• Predictors of response– Age– Preservation of motor CMAP amplitudes pre-PLEX
![Page 52: N EUROMUSCULAR E MERGENCIES July 28, 2010 Sandra Derghazarian](https://reader031.vdocuments.net/reader031/viewer/2022013011/56649ccb5503460f94994bbf/html5/thumbnails/52.jpg)
IVIG
• Dose: 0.4 gm/kg/day x 5 consecutive days• Cheaper, easier to administer• Rare complications– Renal failure, proteinuria, pulmonary edema– Asceptic meningitis– Anaphylaxis in IgA deficiency
![Page 53: N EUROMUSCULAR E MERGENCIES July 28, 2010 Sandra Derghazarian](https://reader031.vdocuments.net/reader031/viewer/2022013011/56649ccb5503460f94994bbf/html5/thumbnails/53.jpg)
Course and Prognosis• Progressive symptoms : 1-4 weeks• Plateau: 2-4 weeks• Recovery: A few weeks to months• Recurrence: 5-10%• Mortality
– 3-5% – Cardiac arrest, ARDS, PTX, HemoTX, PE
• Pronounced disability: 10%– Clinical prognostic indicators
• Greater age • Rapid evolution; early and prolonged ventilatory assistance, rapid course• Lack of treatment with IVIG or plasma exchange
– Laboratory• EMG: severely reduced CMAP and widespread denervation
![Page 54: N EUROMUSCULAR E MERGENCIES July 28, 2010 Sandra Derghazarian](https://reader031.vdocuments.net/reader031/viewer/2022013011/56649ccb5503460f94994bbf/html5/thumbnails/54.jpg)
Pathogenesis
• Most evidence points to cell-mediated immunologic reaction directed at peripheral nerve– May be precipitated by antecedent infection
• Antibodies against myelin components with complement-mediated damage
• T cells and macrophages become involved in process and lead to destruction of myelin/axon
![Page 55: N EUROMUSCULAR E MERGENCIES July 28, 2010 Sandra Derghazarian](https://reader031.vdocuments.net/reader031/viewer/2022013011/56649ccb5503460f94994bbf/html5/thumbnails/55.jpg)
THANK YOU